
## Mireia Sospedra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1597113/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 790884.	2.4	6
2	Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
3	Antigen-Specific Immune Tolerance in Multiple Sclerosis—Promising Approaches and How to Bring Them to Patients. Frontiers in Immunology, 2021, 12, 640935.	4.8	20
4	Multiple sclerosis: doubling down on MHC. Trends in Genetics, 2021, 37, 784-797.	6.7	23
5	T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	18
6	Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 787498.	4.8	5
7	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell, 2020, 183, 1264-1281.e20.	28.9	133
8	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Frontiers in Immunology, 2020, 11, 1188.	4.8	16
9	Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro. Fluids and Barriers of the CNS, 2020, 17, 3.	5.0	64
10	When a T cell engages a B cell: novel insights in multiple sclerosis. Swiss Medical Weekly, 2020, 150, w20330.	1.6	1
11	Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 540.	4.8	31
12	Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e621.	6.0	13
13	B cells in multiple sclerosis. Current Opinion in Neurology, 2018, 31, 256-262.	3.6	48
14	Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e419.	6.0	34
15	GDP- <scp>l</scp> -fucose synthase is a CD4 <sup>+</sup> T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis. Science Translational Medicine, 2018, 10, .	12.4	71
16	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
17	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell, 2018, 175, 85-100.e23.	28.9	350
18	Detailed Characterization of T Cell Receptor Repertoires in Multiple Sclerosis Brain Lesions. Frontiers in Immunology, 2018, 9, 509.	4.8	24

MIREIA SOSPEDRA

#	Article	IF	CITATIONS
19	Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy – a realistic possibility?. Swiss Medical Weekly, 2017, 147, w14520.	1.6	1
20	Mechanisms of immune escape in central nervous system infection with neurotropic <scp>JC</scp> virus variant. Annals of Neurology, 2016, 79, 404-418.	5.3	40
21	OMIPâ€033: A comprehensive single step staining protocol for human T―and B ell subsets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 629-632.	1.5	10
22	Immunology of Multiple Sclerosis. Seminars in Neurology, 2016, 36, 115-127.	1.4	177
23	Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. European Journal of Immunology, 2016, 46, 2078-2090.	2.9	101
24	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
25	Central role of Th2/Tc2 lymphocytes in pattern <scp>II</scp> multiple sclerosis lesions. Annals of Clinical and Translational Neurology, 2015, 2, 875-893.	3.7	45
26	Immunology of progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2015, 21, 614-622.	2.1	36
27	Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. Multiple Sclerosis Journal, 2015, 21, 651-655.	3.0	9
28	Broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy. Science Translational Medicine, 2015, 7, 306ra150.	12.4	38
29	Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Related Outcome Measures, 2014, 5, 25.	1.2	22
30	Adoptive Transfer of EBV Specific CD8+ T Cell Clones Can Transiently Control EBV Infection in Humanized Mice. PLoS Pathogens, 2014, 10, e1004333.	4.7	60
31	Boswellic acids reduce <scp>T</scp> h17 differentiation via blockade of <scp>IL</scp> â€lβâ€mediated <scp>IRAK</scp> 1 signaling. European Journal of Immunology, 2014, 44, 1200-1212.	2.9	25
32	Sphingosine-1 Phosphate and Central Nervous System. Current Topics in Microbiology and Immunology, 2014, 378, 149-170.	1.1	30
33	Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1. Clinical Infectious Diseases, 2014, 59, 1588-1592.	5.8	64
34	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213
35	HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain, 2013, 136, 1783-1798.	7.6	40
36	Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. Journal of Neuroimmunology, 2013, 261, 108-119.	2.3	60

MIREIA SOSPEDRA

#	Article	IF	CITATIONS
37	JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment. Annals of Neurology, 2013, 74, 622-626.	5.3	41
38	Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis. Science Translational Medicine, 2013, 5, 188ra75.	12.4	262
39	T Cell Epitope Mapping of JC Polyoma Virus-Encoded Proteome Reveals Reduced T Cell Responses in HLA-DRB1*04:01 <sup>+</sup> Donors. Journal of Virology, 2013, 87, 3393-3408.	3.4	20
40	Use of Positional Scanning Libraries to Identify Immunologically Relevant Peptides. , 2013, , 617-624.		1
41	TCR Bias and HLA Cross-Restriction Are Strategies of Human Brain-Infiltrating JC Virus-Specific CD4+ T Cells during Viral Infection. Journal of Immunology, 2012, 189, 3618-3630.	0.8	29
42	T Lymphocyte Priming by Neutrophil Extracellular Traps Links Innate and Adaptive Immune Responses. Journal of Immunology, 2012, 188, 3150-3159.	0.8	236
43	Natalizumab treatment perturbs memory―and marginal zoneâ€like Bâ€cell homing in secondary lymphoid organs in multiple sclerosis. European Journal of Immunology, 2012, 42, 790-798.	2.9	95
44	Displacement chromatography as first separating step in online two-dimensional liquid chromatography coupled to mass spectrometry analysis of a complex protein sample—The proteome of neutrophils. Journal of Chromatography A, 2012, 1232, 288-294.	3.7	16
45	Neutrophils in multiple sclerosis are characterized by a primed phenotype. Journal of Neuroimmunology, 2012, 242, 60-71.	2.3	190
46	Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain, 2011, 134, 2687-2702.	7.6	78
47	Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones. Journal of Immunological Methods, 2010, 353, 93-101.	1.4	10
48	Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: Implications for the initiation of the autoimmune response in multiple sclerosis. European Journal of Immunology, 2008, 38, 1297-1309.	2.9	20
49	Antigen-specific therapies in MS — Current concepts and novel approaches. Journal of the Neurological Sciences, 2008, 274, 18-22.	0.6	28
50	Cerebrospinal Fluid-Infiltrating CD4 + T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis. Infection and Immunity, 2007, 75, 243-251.	2.2	22
51	Molecular mimicry in multiple sclerosis. Autoimmunity, 2006, 39, 3-8.	2.6	45
52	When T cells recognize a pattern, they might cause trouble. Current Opinion in Immunology, 2006, 18, 697-703.	5.5	6
53	Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis. Journal of Neuroimmunology, 2006, 171, 177-183.	2.3	20
54	Redundancy in Antigen-Presenting Function of the HLA-DR and -DQ Molecules in the Multiple Sclerosis-Associated HLA-DR2 Haplotype. Journal of Immunology, 2006, 176, 1951-1961.	0.8	49

MIREIA SOSPEDRA

#	Article	IF	CITATIONS
55	Antigen-Specific Therapies in Multiple Sclerosis. International Reviews of Immunology, 2005, 24, 393-413.	3.3	48
56	Recognition of Conserved Amino Acid Motifs of Common Viruses and Its Role in Autoimmunity. PLoS Pathogens, 2005, 1, e41.	4.7	73
57	Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. Journal of Autoimmunity, 2005, 25, 312-318.	6.5	50
58	IMMUNOLOGY OF MULTIPLE SCLEROSIS. Annual Review of Immunology, 2005, 23, 683-747.	21.8	1,982
59	Different patterns of nicotinic acetylcholine receptor subunit transcription in human thymus. Journal of Neuroimmunology, 2004, 149, 147-159.	2.3	18
60	Use of combinatorial peptide libraries for T-cell epitope mapping. Methods, 2003, 29, 236-247.	3.8	41
61	Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. European Journal of Immunology, 2002, 32, 2737-2747.	2.9	82
62	Functional antigen-independent synapses formed between T cells and dendritic cells. Nature Immunology, 2001, 2, 925-931.	14.5	268
63	HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. International Immunology, 1999, 11, 269-277.	4.0	19
64	Singleâ€cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. European Journal of Immunology, 1997, 27, 3290-3302.	2.9	109